تأثير عقار السبروفلوكساسين على مستوى خميرة الفوسفاتيز القاعية في الفئران السليمة
Article Sidebar
Published:
Jun 28, 1999
Keywords:
mice, ciprofloxacin, alkaline phosphates
Main Article Content
Abstract
This study was designed to investigate the effects of ciprofloxacin on-serum alkaline phosphates level in normal mice , the dosage used is treatment and double dose (5
10 mg / kg ) orally for 5 days . The result showed that ciprofloxacin caused a marked increase in serum alkaline phosphates with the increase of dose, and this may be releated to the damage of cell in liver , kidney and bone
Downloads
Download data is not yet available.
Article Details
How to Cite
تأثير عقار السبروفلوكساسين على مستوى خميرة الفوسفاتيز القاعية في الفئران السليمة. (1999). The Iraqi Journal of Veterinary Medicine, 23(1), 79-85. https://doi.org/10.30539/ijvm.v23i1.1195
Section
Articles
How to Cite
تأثير عقار السبروفلوكساسين على مستوى خميرة الفوسفاتيز القاعية في الفئران السليمة. (1999). The Iraqi Journal of Veterinary Medicine, 23(1), 79-85. https://doi.org/10.30539/ijvm.v23i1.1195
References
1-Abadia , A.R. Francisco, L.DE and Guaitani A (1995). Disposition of ciprofloxacin in the isolated perfused rat liver. The American Society for pharmacology and
experimental therapeutics : 23 , 197 - 200.
2-Aramayona J.J; Jaume M; Lorenzo . J Fraile ; Maria A. Grasia; Ana R. Abadia; Miguel A. Bregant (1996). Penetration of enterofloxacin and ciprofloxacin into milk, and pharma cokinetics of the drugs in lactating rabbits and neonatal offspring . AJVR. 57 (4): 547 – 553.
3-Arcier, G.M; Nancy Beker (1989). Safety of intravenous ciprofloxacin . AJM. Nov. 30 ; 87 (suppl 5 A). 92s – 97s)
4-Caekenberge, D.V. Stefanr Pattyn (1984). In vitro activity of ciprofloxacin compared with those new fluorinated piprazinyi supstituted quinoline derevatives.
Antimicrobial agent chemotherapy 25(3) 518-521.
5- Frost, R.W; Lettieri ;. J.T; Krol G; Shambien E.C and Laiseter K.C (1989) . The effect of cirohosis on the steady-state pharmacokinetics of oral ciprofloxacin .
Pharmacol. Ther. 45: 608 – 616.
6-Gudiol F ; Carmen Cabellos ; Roman Pallares; Josefina L; Javier A (1989). Intravenous ciprofloxacin therapy severe infections AJM.
Nov. 30 87 (suppl. 5 A): 2218 -227S.
7- Halkin G. (1988). Adverse effects of the fluoroquinolo - nes . Rview of infectious disease. 10 ( suppl./1 ): 5258 5261.
8- Harper A. Harlod (1971). Review of physiological chemistry (15 th.) edition. Lange . Medical publication . San Francisco. Japan.
9-Neer T.M. (1988). Clinical pharmacological features of fluoroquinolone antimicrobial drugs .JAVMA. 193 (5): 577 -579.
10- Richards D.M; Mouk J.P; Price . A; Field . B; Todd P.A. and ward (1988). Ciprofloxacin : a review of its antibacterial activity pharmacokinetic properties and
therapeutics use . Drugs . 53, 373 – 447.
11- Schacht P; hullman R. (1989) Safety of oral ciprofloxacin . A.JM. 87 (suppl. 5A ): 989 -102s.
12- Schalm D.W; Jain N.C. and Carroll E.J. (1980) Veterinary hematology (4'h.) edition . P(514). Lea Febbiger , Philadelphia
13- Shah, P.M; Rotraud M (1990) · Safety profile of quinolones . Eur. Uro ; 17(suppl / 1): 46 – 51 (13ref).
14- Villenenve, J.P; Davies C and Cote J. (1995) suspected ciprofloxacin induced hepatotxicity. Ann.
Pharmacotherapy , 29: 257 – 259.
15- Wolfson, J.S. and Hooper D.C. (1985) . The fluoro quinolones structure , mechanism of action resistance and spectra of activity invitro. Antimicrob .Agents and Chemother.
28: 581 - 586.
experimental therapeutics : 23 , 197 - 200.
2-Aramayona J.J; Jaume M; Lorenzo . J Fraile ; Maria A. Grasia; Ana R. Abadia; Miguel A. Bregant (1996). Penetration of enterofloxacin and ciprofloxacin into milk, and pharma cokinetics of the drugs in lactating rabbits and neonatal offspring . AJVR. 57 (4): 547 – 553.
3-Arcier, G.M; Nancy Beker (1989). Safety of intravenous ciprofloxacin . AJM. Nov. 30 ; 87 (suppl 5 A). 92s – 97s)
4-Caekenberge, D.V. Stefanr Pattyn (1984). In vitro activity of ciprofloxacin compared with those new fluorinated piprazinyi supstituted quinoline derevatives.
Antimicrobial agent chemotherapy 25(3) 518-521.
5- Frost, R.W; Lettieri ;. J.T; Krol G; Shambien E.C and Laiseter K.C (1989) . The effect of cirohosis on the steady-state pharmacokinetics of oral ciprofloxacin .
Pharmacol. Ther. 45: 608 – 616.
6-Gudiol F ; Carmen Cabellos ; Roman Pallares; Josefina L; Javier A (1989). Intravenous ciprofloxacin therapy severe infections AJM.
Nov. 30 87 (suppl. 5 A): 2218 -227S.
7- Halkin G. (1988). Adverse effects of the fluoroquinolo - nes . Rview of infectious disease. 10 ( suppl./1 ): 5258 5261.
8- Harper A. Harlod (1971). Review of physiological chemistry (15 th.) edition. Lange . Medical publication . San Francisco. Japan.
9-Neer T.M. (1988). Clinical pharmacological features of fluoroquinolone antimicrobial drugs .JAVMA. 193 (5): 577 -579.
10- Richards D.M; Mouk J.P; Price . A; Field . B; Todd P.A. and ward (1988). Ciprofloxacin : a review of its antibacterial activity pharmacokinetic properties and
therapeutics use . Drugs . 53, 373 – 447.
11- Schacht P; hullman R. (1989) Safety of oral ciprofloxacin . A.JM. 87 (suppl. 5A ): 989 -102s.
12- Schalm D.W; Jain N.C. and Carroll E.J. (1980) Veterinary hematology (4'h.) edition . P(514). Lea Febbiger , Philadelphia
13- Shah, P.M; Rotraud M (1990) · Safety profile of quinolones . Eur. Uro ; 17(suppl / 1): 46 – 51 (13ref).
14- Villenenve, J.P; Davies C and Cote J. (1995) suspected ciprofloxacin induced hepatotxicity. Ann.
Pharmacotherapy , 29: 257 – 259.
15- Wolfson, J.S. and Hooper D.C. (1985) . The fluoro quinolones structure , mechanism of action resistance and spectra of activity invitro. Antimicrob .Agents and Chemother.
28: 581 - 586.